Stock Market Research
Data-driven company analysis and original studies from Equibles, grounded in disclosed primary sources and documented methods.
Rocket Lab: Backlog is converting, but the $39B market cap is paying for a Neutron debut the company has yet to validate
Rocket Lab enters Q2 2026 with record backlog of $2,219.8M and guided revenue of $225.0M–$240.0M, yet the stock trades at -55.2% from its $150.23 high on a $39.0B market cap against $679.6M of trailing revenue — a gap the equity-funded growth model and the un-flown Neutron debut have to close.
Emergent BioSolutions: leveraged biodefense name trades like a Narcan story while international MCM mix hits 37%
A $413.3M small-cap MCM franchise that has signed a $140M Canada agreement, a $54M ASPR award, and an ACAM2000 modification while net leverage fell to 1.9x and a $50M buyback was reauthorized — yet the equity is the worst YTD performer in the peer set with 19.9% short interest, leaving the print of the next four quarters to test whether the international MCM pivot can offset the Narcan generics drag.
Alexandria Real Estate Equities: stress event priced in, dividend reset is the test
Alexandria Real Estate Equities sits at a -38.8% trailing-twelve-month change and a -45.0% drawdown from its 52-week high after cutting its dividend from $1.32 to $0.72 and reporting zero public biotech leasing for the first quarter in company history. The peer office REIT cohort is reporting tightening markets and raising FFO midpoints, leaving ARE's stress specific to its public-biotech exposure — the setup turns on whether the 1.1 million square feet of leased vacant space delivers in September 2026, the $2.2 billion disposition program closes on pace, and public biotech leasing returns in Q2.